These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 30277862)

  • 41. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
    Campochiaro C; Allanore Y
    Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systemic sclerosis (scleroderma): remaining challenges.
    Connolly MK
    Ann Transl Med; 2021 Mar; 9(5):438. PubMed ID: 33842659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement.
    De Luca G; Cavalli G; Campochiaro C; Bruni C; Tomelleri A; Dagna L; Matucci-Cerinic M
    Front Immunol; 2021; 12():653950. PubMed ID: 33833766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of Alarmins in the Pathogenesis of Systemic Sclerosis.
    Giovannetti A; Straface E; Rosato E; Casciaro M; Pioggia G; Gangemi S
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 46. Is biological therapy in systemic sclerosis the answer?
    Misra DP; Ahmed S; Agarwal V
    Rheumatol Int; 2020 May; 40(5):679-694. PubMed ID: 31960079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Roles of IL-1 Family Cytokines in the Pathogenesis of Systemic Sclerosis.
    Xu D; Mu R; Wei X
    Front Immunol; 2019; 10():2025. PubMed ID: 31572353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis.
    Birnhuber A; Crnkovic S; Biasin V; Marsh LM; Odler B; Sahu-Osen A; Stacher-Priehse E; Brcic L; Schneider F; Cikes N; Ghanim B; Klepetko W; Graninger W; Allanore Y; Eferl R; Olschewski A; Olschewski H; Kwapiszewska G
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31320452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Probing Anti-inflammatory Properties Independent of NF-κB Through Conformational Constraint of Peptide-Based Interleukin-1 Receptor Biased Ligands.
    Geranurimi A; Cheng CWH; Quiniou C; Zhu T; Hou X; Rivera JC; St-Cyr DJ; Beauregard K; Bernard-Gauthier V; Chemtob S; Lubell WD
    Front Chem; 2019; 7():23. PubMed ID: 30815434
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review.
    Fernández-Lázaro D; Iglesias-Lázaro M; Garrosa E; Rodríguez-García S; Jerves Donoso D; Gutiérrez-Abejón E; Jorge-Finnigan C
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837449
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.
    Schwier NC
    Ann Pharmacother; 2022 May; 56(5):572-581. PubMed ID: 34459270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.
    Mantero JC; Kishore N; Ziemek J; Stifano G; Zammitti C; Khanna D; Gordon JK; Spiera R; Zhang Y; Simms RW; Lafyatis R
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):146-149. PubMed ID: 30277862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.
    Quillinan NP; McIntosh D; Vernes J; Haq S; Denton CP
    Ann Rheum Dis; 2014 Jan; 73(1):56-61. PubMed ID: 24067785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
    Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
    Allanore Y; Wung P; Soubrane C; Esperet C; Marrache F; Bejuit R; Lahmar A; Khanna D; Denton CP;
    Ann Rheum Dis; 2020 Dec; 79(12):1600-1607. PubMed ID: 32963047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Khanna D; Spino C; Johnson S; Chung L; Whitfield ML; Denton CP; Berrocal V; Franks J; Mehta B; Molitor J; Steen VD; Lafyatis R; Simms RW; Gill A; Kafaja S; Frech TM; Hsu V; Domsic RT; Pope JE; Gordon JK; Mayes MD; Schiopu E; Young A; Sandorfi N; Park J; Hant FN; Bernstein EJ; Chatterjee S; Castelino FV; Ajam A; Wang Y; Wood T; Allanore Y; Matucci-Cerinic M; Distler O; Singer O; Bush E; Fox DA; Furst DE
    Arthritis Rheumatol; 2020 Jan; 72(1):125-136. PubMed ID: 31342624
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.